Skip to main content

Table 1 Patients' clinical characteristics and outcomesa

From: Hormonal status in protracted critical illness and in-hospital mortality

Patient demographics, N= 102 (100%) Data
Median age, yr (IQR) 66 (51 to 78)
COPDb, n (%) 39 (38%)
Chronic cardiac insufficiencyb, n (%) 28 (27.5%)
Medical admission, n (%) 71 (69.6%)
Median SAPS II at ICU admission (IQR) 46 (38 to 55)
From admission to awakening (day 1)  
   Septic shockc, n (%) 53 (52%)
   Median days with failure of ≥2 organsd, days (IQR) 8 (7 to 11)
   Median duration of mechanical ventilation, days (IQR) 10.0 (8.0 to 14.0)
   Mean blood glucose, mM/l (IQR) 7.6 (6.9 to 8.8)
   Use of vasopressors, n (%) 77 (75%)
   Use of corticosteroids, n (%) 64 (63%)
   Median corticosteroid dose, 103 g (IQR) 1.0 (0 to 1.9)
   Median delay from steroid administration to day 1, days (IQR) 3.0 (1.0 to 8.0)
   Use of NMBA, n (%) 40 (39%)
At awakening (day 1, n = 86)  
   Median SAPS II (IQR) 30 (23 to 26)
After awakening  
   Median ICU length of stay, days (IQR) 23 (15 to 35)
   ICU mortality, n (%) 15 (15%)
   In-hospital mortality, n (%) 24 (24%)
  1. aIQR, interquartile range; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score II [15]; NMBA, neuromuscular blocking agent; bdiagnosis of COPD and chronic cardiac insufficiency were based on clinical history; cseptic shock was defined as the administration of catecholamines and a concomitant documented infection after exclusion of other causes of shock; drenal, hepatic, and hematological failure were defined according to the Organ Dysfunctions and/or Infection score [16].